Intellicyt Corporation – Trademark Portfolio
Entity Type: 03
Intellicyt Corporation owns a portfolio of 15 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as IQUE, QBEADS, FORECYT, VIROTAG, and HYPERVIEW. Of these, 6 are registered. The portfolio spans 3 Nice Classification classes, led by Class 1 (Chemicals) and Class 9 (Computers & Electronics). Headquartered in Albuquerque, NM.
9620 San Mateo Blvd. NE
Albuquerque, NM 87113
Showing of trademarks Trademarks
Trademark Classifications
Intellicyt Corporation's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Intellicyt Corporation have?
Intellicyt Corporation has 15 U.S. trademarks filed with the USPTO. Of these, 6 registered, 2 abandoned, 7 cancelled.
What trademark classes does Intellicyt Corporation file in?
Intellicyt Corporation files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are Intellicyt Corporation's most well-known trademarks?
Intellicyt Corporation's registered trademark portfolio includes well-known marks such as IQUE, QBEADS, FORECYT, VIROTAG, and HYPERVIEW. These are among 6 currently registered trademarks in the portfolio.
What is Intellicyt Corporation's trademark registration success rate?
Intellicyt Corporation has a 40% trademark registration rate, with 6 out of 15 resolved applications resulting in successful registration. Currently, 0 applications are pending review.